### Check for updates

### OPEN ACCESS

EDITED BY Rudolf Lucas, Augusta University, United States

### REVIEWED BY

Ranya Elsayed, Augusta University, United States Hengyi Xu, The University of Texas at Austin, United States Zhengyang Zhou, University of North Texas Health Science Center, United States

\*CORRESPONDENCE Yanmin Wu Wuyanmin@zju.edu.cn

<sup>†</sup>These authors have contributed equally to this work and share first authorship

RECEIVED 29 April 2023 ACCEPTED 13 July 2023 PUBLISHED 31 July 2023

### CITATION

Hu G, Song C, Yang Y, Wang W, Wang A, Huang M, Lei L and Wu Y (2023) Causal relationship between circulating lipid traits and periodontitis: univariable and multivariable Mendelian randomization. *Front. Endocrinol.* 14:1214232. doi: 10.3389/fendo.2023.1214232

### COPYRIGHT

© 2023 Hu, Song, Yang, Wang, Wang, Huang, Lei and Wu. This is an open-access article distributed under the terms of the **Creative Commons Attribution License** (**CC BY**). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Causal relationship between circulating lipid traits and periodontitis: univariable and multivariable Mendelian randomization

### Gaofu Hu<sup>1†</sup>, Chengjie Song<sup>1†</sup>, Yuxuan Yang<sup>1</sup>, Wenhao Wang<sup>1</sup>, Ao Wang<sup>1</sup>, Mei Huang<sup>2</sup>, Lihong Lei<sup>1</sup> and Yanmin Wu<sup>1\*</sup>

<sup>1</sup>Department of Periodontology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, <sup>2</sup>Periodontology Unit, University College London Eastman Dental Institute, London, United Kingdom

**Introduction:** The correlation between dyslipidemia and periodontitis is revealed through epidemiological studies. However, the results are affected by several confounding factors. This study aims to elucidate the genetic causal association between circulating lipid traits and periodontitis by two-sample Mendelian randomization (MR) analysis.

**Methods:** After the different screening processes, two cohorts of circulating lipid traits from the UK Biobank were used as exposure data, including five circulating lipid traits. The Periodontitis cohort was selected from the GeneLifestyle Interactions in Dental Endpoints (GLIDE) consortium as outcome data. In univariable MR, the inverse variance weighted (IVW) was used in conjunction with six additional analytical methods to assess causality. The Cochran Q test,  $I_{GX}^2$  statistic, MR-PRESSO, and MR-Egger intercept were used to quantify heterogeneity and pleiotropy. The multivariable MR-IVW (MVMR-IVW) and MVMR-robust were mainly used as analytical methods in the multiple MR analyses.

**Results:** The IVW estimates showed that genetically predicted Apolipoprotein A1 (apo A1) [odds ratio (OR)=1.158, 95% confidence interval (CI)=1.007–1.331, *P*-value=0.040] was potentially associated with the risk of periodontitis, but the statistical power of the results was low. Multivariable MR analysis did not reveal any significant causal relationship between apo A1 and periodontitis (OR=0.72, 95% CI=0.36–1.41, *P*-value=0.34). In the validation cohort, there was also no significant causal relationship between apo A1 and periodontitis (OR=1.079, 95% CI=0.903–1.290, *P*-value=0.401). Meanwhile, genetically predicted Apolipoprotein B (apo B), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) (all *P*-values>0.05) were not significantly associated with the risk of periodontitis causal inference.

**Conclusion:** This MR analysis was unable to provide genetic evidence for the influence of these five circulating lipid traits on periodontitis. However, a more extensive study with a more comprehensive circulating lipid profile and periodontitis data is needed due to study limitations.

KEYWORDS

lipid traits, periodontitis, Mendelian randomization, genetic correlation, causality

## 1 Introduction

Periodontitis is a chronic inflammatory disease caused by dysbiosis. It leads to periodontal soft tissue inflammation, continuous loss of alveolar bone, and eventually results in tooth loosening and loss (1). According to the fourth National Oral Health Survey data in China, 90% of people over 35 years old in three age groups have periodontal diseases of varying degrees, among which 30% suffer from stage III to stage IV periodontitis (2). Globally, the proportion of severe periodontitis amounts to 23.6%, which has become the sixth-largest epidemic (3). Therefore, it is essential to intervene in the risk factors of periodontitis, among which the systemic factors have been paid more and more attention. A considerable amount of epidemiological and experimental evidence has confirmed that various systemic diseases, such as cardiovascular diseases, diabetes, and respiratory diseases, play a vital role in the initiation and progression of periodontitis (4). Dyslipidemia is a condition with elevated plasma concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or triglyceride (TG), low plasma levels of high-density lipoprotein cholesterol (HDL-C), or a combination of these characteristics. Global data from 2008 showed that about 39% of adults (over 25 years old) had elevated levels of total lipid cholesterol, with the highest prevalence in Europe (5). More importantly, evidence suggests that patients with high lipid levels also have an increased level of systemic inflammation (6), which subsequently increases the risk of periodontitis in patients.

A recent US national cross-sectional study found that dyslipidemia had a significant direct impact on periodontitis and was associated with periodontitis through an indirect pathway of glycated hemoglobin (7). Another nationwide cohort study among women also showed that LDL-C levels were positively correlated, while HDL-C levels were negatively correlated with periodontitis risk. However, no such association was found with periodontitis risk in male subjects (8). In the case of hyperlipidemia combined with periodontitis, the probing depth (PD) and clinical attachment loss (CAL) of patients were positively correlated with the levels of TG, TC, and LDL-C (9, 10). Another cross-sectional study also showed that in patients with chronic periodontitis, the level of apolipoprotein B (apo B) in gingival crevicular fluid in the infected area was higher than that in the healthy area (11). It is well established that periodontitis and dyslipidemia share several risk factors, such as diabetes, age, obesity, alcohol consumption, smoking, etc. (12, 13). Despite the conflicting findings from different studies, there was still evidence indicating a possible

association between circulating lipid traits and periodontitis. Traditional epidemiological studies, which had been subjected to such confounders and influenced by reverse causality, were found to be challenging to establish these associations as causation.

Mendelian randomization (MR) is an analysis method based on genome-wide association study (GWAS) data. It combines the Mendelian law of segregation with the instrumental variable approach (14). The former means that the alleles located on the homologous chromosomes of the parents will segregate at meiosis and can be randomly assigned to the offspring. The natural randomness of the process can mimic the randomized controlled study (RCT), similar to randomization effects (15). The latter can use single-nucleotide polymorphisms (SNPs) as instrumental variables (IVs) in the presence of unknown confounding factors and use the effect of SNPs and outcome to simulate the causal relationship between "exposure-outcome" (16). MR can overcome the limitations of conventional epidemiological studies, which is why we are using MR to look at disease correlation.

The selection of HDL-C, LDL-C, and TG as exposures in this trial was based on their widespread use in guidelines for dyslipidemia screening (17-19). LDL is efficient in transporting the majority of cholesterol in the bloodstream, whilst HDL plays a pivotal role in enabling reverse cholesterol transport from peripheral tissues to the liver. Both of these lipoproteins exert a considerable influence on plasma cholesterol levels (20). Furthermore, the inclusion of apo A1, known for its protective role against atherosclerosis and modulation of lipid metabolism, along with apo B, which encompasses all atherogenic lipoprotein particles, was also deemed necessary as additional exposures (18, 19, 21). To explore the causal relationship between five circulating lipid traits (apo A1, apo B, HDL-C, LDL-C, and TG) and the risk of periodontitis, this study conducted a two-sample univariable and multivariable MR study using data from the UK Biobank (UKB) (RRID: SCR\_012815) and GeneLifestyle Interactions in Dental Endpoints (GLIDE) consortium. Each trait was evaluated independently for periodontitis risk.

### 2 Methods

### 2.1 Data sources

Genetic variation associated with circulating lipid traits was obtained from a recently published meta-analysis of genome-wide association studies (GWAS). The study assessed 35 blood and urine biomarkers in UKB based on their genetics after adjusting for statin usage, including the following five circulating lipid traits: apo A1 (N=290,198), apo B (N=317,412), HDL-C (N=291,830), LDL-C (N=318,340), and TG (N=318,674) (22). Genetic statistics of other circulating lipid traits were invoked as a validation cohort. This GWAS excluded individuals with sex mismatch or sexchromosomal aneuploidy in the UKB. Also, it included five circulating lipid traits: apo A1 (N=115,082), apo B (N=115,082), HDL-C (N=115,082), LDL-C (N=115,082), and TG (N =115,082) (23). UKB is a large-scale biomedical cohort research database initiated and established by the UK government and long-term follow-up of participants' health (24). Summary statistics for periodontitis were derived from the GWAS of the European Study of the GLIDE consortium, which included 17,353 periodontitis cases and 28,210 controls (25). The diagnosis of periodontitis cases is based primarily on the Centers for Disease and Control and Prevention/American Academy of Periodontology (CDC/AAP). Due to a lack of specific clinical examination data for each patient, it is impossible to get accurate staging and grading of periodontitis for patients included in this GWAS. The characteristics of the GWAS consortiums used for each variable are presented in Table 1.

### 2.2 Study design

Univariable MR analysis was applied to determine if genetically predicted circulating lipid traits were significantly related to periodontitis risk, and the data from another GWAS was used for validation. Multivariable MR analysis was then conducted to determine the independent influences of the five circulating lipid traits. Genetic instrument variables (IVs) used in MR analysis to estimate the impact must comply with three main assumptions (26) (Figure 1): (1) Genetic variation should be significantly associated with circulating lipid traits; (2) Genetic variation must not be

TABLE 1 Characteristics of GWAS consortiums used for each variable.

associated with any confounding factors; (3) Genetic variation must be associated with periodontitis only through circulating lipid traits. This study was reported following the recommendations of the latest STROBE-MR (Strengthening the Reporting of Observational studies in Epidemiology-Mendelian randomization) (Supplementary Table 1). Ethical approval and informed consent for this experiment can be obtained from the original study. The research design and route are shown in Figure 1.

### 2.3 Selection of instrumental variables


To make the IV candidates conform to the above three hypotheses, we first selected the SNPs significantly associated with apo A1, apo B, HDL-C, LDL-C, and TG in GWAS (P-value<5×10<sup>-8</sup>). Then an aggregation procedure with r<sup>2</sup><0.001 and a window size=10,000 kb was performed based on 1000 Genomes Project European samples, excluding SNPs in linkage disequilibrium (LD), among which SNPs with lower P-values will be retained. Next, we removed SNPs that were not present in the outcome. To ensure that the selected SNPs have corresponding alleles, SNPs with inconsistent alleles and ambiguous palindromic SNPs were eliminated or adjusted. After initial screening, it was necessary to remove any potential confounding factors associated with SNPs that may affect the results. After searching for PhenoScanner V2 (http://www.phenoscanner.medschl.cam.ac.uk/, accessed on September 29, 2022) (27), blood pressure, glucose, body mass index (BMI), C-reactive protein (CRP), circulating blood cell profiles, coronary artery disease (CAD), and inflammatory bowel disease (IBD) were identified as confounding factors. To ensure the strength of the IVs, we calculated the F-statistic for each SNP:

$$F = \beta^2 / SE^2$$
$$R^2 = F / (N - 2 + F)$$

where  $\beta$  represented the genetic effect of each SNP on the exposure, *SE* was the standard error effect estimate of the corresponding

			I.
Exposure/Outcomes	Consortium	Ethnicity	Sample Sizes
apo A1	UKB	European	290,198
apo B	UKB	European	317,412
HDL-C	UKB	European	291,830
LDL-C	UKB	European	318,340
TG	UKB	European	318,674
apo A1 (validation)	UKB	European	115,082
apo B (validation)	UKB	European	115,082
HDL-C (validation)	UKB	European	115,082
LDL-C (validation)	UKB	European	115,082
TG (validation)	UKB	European	115,082
Periodontitis	GLIDE	European	45,563

apo A1, Apolipoprotein A1; apo B, Apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.



cholesterol; TG, triglyceride.

GWAS, N was the sample size, and was the exposure variance explained by the selected IVs (28). When the *F*-statistic was much larger than 10, the IVs were less likely to be considered weak instruments (29). The determination of power in MR analyses relies on several factors, including the extent to which genetic variants account for the variance in circulating lipid traits, the overall sample size of the periodontitis GWAS, and the proportion of individuals affected by periodontitis. Subsequently, odds ratios (ORs) are computed with 80% power to address the issue of inadequate statistical capacity and guarantee the dependability of subsequent findings (30). Power calculators can be accessed at http:// cnsgenomics.com/shiny/mRnd/.

### 2.4 Statistical analysis

To obtain more accurate MR estimates, we combined several two-sample MR statistical methods to assess the causal relationship between exposure and outcome. The inverse variance weighted (IVW) is the primary method for inferring causality, and it calculates the weighted average of the Wald estimates for each selected SNP (30). This method will provide the most reliable results when pleiotropy is not present in the IVs. Based on different assumptions of horizontal pleiotropy, we also employed four complementary approaches [the MR-Egger regression, the weighted median (WM), the weighted mode, and the simple mode] for inferring causality (31-33). Bayesian weighted Mendelian randomization (BWMR) further considers the uncertainty of weak effects while allowing for pleiotropy. The causal inference is performed through the variational expectation maximization (VEM) algorithm, and the results of BWMR are also reliable (34). Due to the low number of SNPs representing partial exposure after screening in the validation cohort, the penalized weighted median (PWM) method was adopted for supplementary analysis, which can minimize the impact of outliers (32). The Cochran Q test,  $I_{GX}^2$ statistic, and MR-Egger intercept were used to quantify heterogeneity and pleiotropy (31). Second, to eliminate the influence of a single SNP, we used the leave-one-out analysis to evaluate the robustness of the results. Third, the asymmetry of the funnel plot was used to assess the reliability of the results (35). Finally, MR-PRESSO was used to test and remove horizontal pleiotropic outliers (36).

# 2.5 Multivariable Mendelian randomization analysis

Next, multivariable MR was carried out to obtain the independent effect of each circulating lipid trait on periodontitis (37). The multivariable MR analyzed the overlapping SNPs among the five circulating lipid traits after the above screening. Based on MM-estimation, using the MVMR-robust method can provide low bias and robust causality at different levels of pleiotropy (38).

For the number of exposures in this study, after the Bonferroni correction, a *P*-value<0.01 (0.05/5) was considered significantly associated, and  $0.01 \le P$ -value<0.05 was considered potentially associated. R statistical software, version 4.1.3 (R Foundation, Vienna, Austria) with the TwoSampleMR 0.5.6 (35), MRPRESSO 1.0 (36), BWMR 0.1.1 (34), and MVMR 0.3 (39) package was used for all analyses.

# **3** Results

# 3.1 Univariable MR analysis of the circulating lipids traits in connection with periodontitis

After the above screening process, we selected 68, 69, 77, 85, and 51 SNPs as the IVs of apo A1, apo B, HDL-C, LDL-C, and TG. The F-statistics of all SNPs were more significant than 10 (range,

29.521-1111.513), indicating that causal estimates were unlikely to be affected by weak instruments (Supplementary Table 2). The minimum detectable OR for each circulating lipid trait was at 80% power of periodontitis and  $\alpha$ =5%, the expected OR were ≤0.82 or ≥1.21 for apo A1, ≤0.76 or ≥1.29 for apo B, ≤0.80 or ≥1.23 for HDL-C, ≤0.78 or ≥1.26 for LDL-C, and ≤0.69 or ≥1.40 for TG (Supplementary Table 3).

Univariable MR analysis results showed that apo A1 might have a causal connection with periodontitis, but not apo B, HDL-C, LDL-C, or TG. IVW showed that apo A1 was the only one potentially linked to periodontitis [odds ratio (OR)=1.158, 95% confidence interval (CI)=1.007-1.331, P-value=0.040]. Besides, the BWMR (OR=1.160, 95% CI=1.008-1.336, P-value=0.038) and the MR-PRESSO (OR=1.158, 95% CI=1.018-1.317, P-value=0.029) supported this result as well (Figure 2). At the same time, MR-PRESSO (P-value for Global Test>0.05), Cochran Q test (Pvalue>0.05),  $I_{GX}^2$  statistics (I<sup>2</sup> = 0.000), and MR-Egger test (Egger intercept=-0.0005, P-value>0.05) also showed that IVs had no heterogeneity and horizontal pleiotropy (Table 2). However, the OR calculated by the three models did not meet the minimum detectable OR of apo A1, which indicated that the causal estimation between apo A1 and periodontitis was at low strength. IVW also suggested no significant causal relationship between the remaining four circulating lipid traits and periodontitis (all P-values>0.05). Six other MR analyses (MR-Egger, WM, simple mode, weighted mode, BWMR, and MR-PRESSO) also showed the same results (Figure 2). The analysis also had no heterogeneity or horizontal pleiotropy (Supplementary Table 4).

We also validated results using different GWAS on circulating lipid traits, and the univariable MR showed that none of the five circulating lipid traits had a significant causal relationship with periodontitis (Figure 3). The *F*-statistics of all SNPs were more extensive than 10 (range, 30.199-367.167), indicating that causal estimates were unlikely to be affected by weak instruments (Supplementary Table 7). There was likewise no heterogeneity or horizontal pleiotropy among all SNPs (Table 3).

The MR-PRESSO outlier test and the leave-one-out analysis showed that all the above results were unaffected by outliers. Leaveone-out analysis diagrams, scatter plots, and funnel plots are all shown in Supplementary Figures 1-10.

# 3.2 Multivariable MR analysis of the circulating lipids traits in connection with periodontitis

We screened 181 SNPs as IVs of multivariable MR to analyze how the different circulating lipid traits affect periodontitis independently (Supplementary Table 8). MVMR-IVW estimate showed that apo A1 (OR=0.72, 95% CI=0.36–1.41, *P*-value=0.34), apo B (OR=1.99, 95% CI=0.68–5.86, *P*-value=0.21), HDL-C (OR=1.38, 95% CI=0.68–2.81, *P*-value=0.37), LDL-C(OR=0.57, 95% CI=0.20–1.66, *P*-value=0.30) and TG (OR=0.94, 95% CI=0.69–1.29, *P*-value=0.71) were not significantly associated with the risk of periodontitis (Figure 4). The remaining four multivariable MR analysis methods also did not obtain evidence

Exposure	Methods	nSNP		OR (95%CI)	P-valu
Apolipoprotein A1	IVW	68		1.158(1.007-1.331)	0.040
	MR-Egger	68	F	1.173(0.932-1.478)	0.179
	Weighted median	68		1.233(0.979-1.552)	0.07
	Simple mode	68	I	1.246(0.816-1.904)	0.31
	Weighted mode	68	••••••	1.276(0.998-1.631)	0.05
	BWMR	68		1.160(1.008-1.336)	0.03
	MR-PRESSO	68	3···•	1.158(1.018-1.317)	0.02
Apolipoprotein B	IVW	69	F∳●I	1.158(0.949-1.412)	0.14
	MR-Egger	69		0.883(0.532-1.465)	0.63
	Weighted median	69	I	0.954(0.721-1.262)	0.74
	Simple mode	69	II	0.932(0.510-1.704)	0.82
	Weighted mode	69	······	0.898(0.544-1.483)	0.676
	BWMR	69	F∲●I	1.161(0.949-1.419)	0.14
	MR-PRESSO	69		1.158(0.969-1.384)	0.11
HDL - cholesterol	IVW	77	Here de la companya d	0.951(0.813-1.113)	0.53
	MR-Egger	77	·····	0.928(0.703-1.224)	0.59
	Weighted median	77	<b> </b>	0.961(0.762-1.213)	0.73
	Simple mode	77	I	1.383(0.825-2.321)	0.22
	Weighted mode	77		0.799(0.577-1.108)	0.18
	BWMR	77	H	0.951(0.811-1.114)	0.53
	MR-PRESSO	77	le• <b>e</b> t•t	0.951(0.831-1.088)	0.46
LDL - cholesterol	IVW	85	⊨	1.125(0.939-1.348)	0.20
	MR-Egger	85	F	0.854(0.549-1.328)	0.48
	Weighted median	85	·····•	1.027(0.793-1.330)	0.84
	Simple mode	85	H	1.118(0.602-2.077)	0.72
	Weighted mode	85	F	0.948(0.568-1.583)	0.84
	BWMR	85		1.130(0.941-1.358)	0.19
	MR-PRESSO	85	·····	1.125(0.960-1.319)	0.14
Triglycerides	IVW	51		0.937(0.718-1.224)	0.63
	MR-Egger	51	II	0.987(0.490-1.989)	0.97
	Weighted median	51	+	0.961(0.656-1.408)	0.83
	Simple mode	51		0.862(0.403-1.844)	0.70
	Weighted mode	51		0.933(0.467-1.864)	0.84
	BWMR	51		0.940(0.717-1.233)	0.65
	MR-PRESSO	51		0.937(0.734-1.198)	0.60

### FIGURE 2

Univariable MR results of circulating lipids traits and periodontitis. The red dots represent the estimates using MR analysis, and the black bars represent the 95% confidence intervals of estimates. The OR>1 indicates increased risk while<1 indicates decreased risk. Results with *P*-value<0.05 but larger than the Bonferroni corrected significance level (0.05/5 = 0.01) were considered as suggestive associations. SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IVW, inverse variance weighted; BWMR, Bayesian weighted Mendelian randomization; HDL-cholesterol, high-density lipoprotein cholesterol; LDL- cholesterol, low-density lipoprotein cholesterol. \* Results with *P*-value<0.05 but larger than the Bonferroni corrected significance level (0.05/5=0.01) were considered as suggestive associations.

of causality. These results were consistent with the univariable MR analysis.

# 4 Discussion

This is the first study investigating the causal correlation between five circulating lipid traits and periodontitis by univariable and multivariable MR. Although univariable MR suggested a potential association of apo A1 with periodontitis, the strength of this finding was low, and analyses of the validation cohort also refuted this association. Therefore, our two-sample MR analysis did not observe robust evidence supporting a causal association of these circulating lipid traits with periodontitis.

However, epidemiological studies have pointed out that apo A1, apo B, HDL-C, LDL-C, and TG are associated with periodontitis. A cross-sectional study involving 123 patients with hyperlipidemia showed that hyperlipidemia significantly increased the severity of periodontitis (OR=2.48, 95% CI=0.63–9.76, *P*-value=0.019) (40). Another case-control study of 13,584 participants, all from the Fifth

TABLE 2 Heterogeneity and pleiotropy tests of circulating lipids traits causally linked to periodontitis.

Exposure	MR-PRESSO <i>P</i> -value for Global Test	IVW				MR-Egger test		
		Cochran's Q	df	<sup>2</sup>	<i>P</i> -value	Egger-intercept	SE	<i>P</i> -value
apo A1	0.794	56.795	67	0.000	0.809	-0.0005	0.004	0.888
apo B	0.875	54.853	68	0.000	0.875	0.0072	0.006	0.258
HDL-C	0.954	56.042	76	0.000	0.958	0.0009	0.004	0.832
LDL-C	0.939	64.785	84	0.000	0.941	0.0072	0.005	0.183
TG	0.759	42.249	50	0.000	0.774	-0.0012	0.008	0.877

apo A1, Apolipoprotein A1; apo B, Apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; IVW, inverse variance weighted.

Exposure Apolipoprotein A1	Methods IVW	<b>nSNP</b> 31	[·····]	OR (95%CI) 1.079(0.903-1.290)	P-value 0.401
Apolipoprotein A i		31		0.927(0.663-1.298)	0.663
	MR-Egger	31		, ,	0.634
	Weighted median			1.065(0.822-1.379)	
	Simple mode	31	······	1.015(0.674-1.628)	0.943
	Weighted mode	31		1.211(0.812-1.805)	0.356
	BWMR	31	I	1.082(0.904-1.296)	0.389
	Penalized weighted median	31		1.065(0.830-1.367)	0.619
	MR-PRESSO	31	 	1.079(0.941-1.238)	0.283
Apolipoprotein B	IVW	11	I	1.123(0.822-1.534)	0.467
	MR-Egger	11		0.697(0.320-1.520)	0.388
	Weighted median	11	I	1.152(0.761-1.745)	0.503
	Simple mode	11		1.199(0.636-2.258)	0.587
	Weighted mode	11	I	1.177(0.703-1.970)	0.549
	BWMR	11		1.129(0.822-1.551)	0.454
	Penalized weighted median	11	······	1.152(0.773-1.719)	0.487
	MR-PRESSO	11	F	1.123(0.842-1.498)	0.449
HDL - cholesterol	IVW	26	<b> </b>	1.026(0.848-1.240)	0.793
	MR-Egger	26		1.039(0.715-1.509)	0.842
	Weighted median	26	····	1.094(0.837-1.431)	0.512
	Simple mode	26	<b> </b>	1.241(0.806-1.913)	0.337
	Weighted mode	26		1.169(0.819-1.667)	0.398
	BWMR	26	···•	1.027(0.848-1.245)	0.783
	Penalized weighted median	26		1.095(0.847-1.414)	0.490
	MR-PRESSO	26		1.026(0.871-1.208)	0.764
LDL - cholesterol	IVW	9	······	1.011(0.658-1.554)	0.959
EDE - Cholesteror	MR-Egger	9		0.513(0.203-1.294)	0.200
	Weighted median	9	· · · · · · · · · · · · · · · · · · ·	0.987(0.597-1.630)	0.250
	Simple mode	9	· · · · · · · · · · · · · · · · · · ·	1.182(0.554-2.520)	0.939
	Weighted mode	9			0.942
	BWMR	9		1.028(0.493-2.146)	
		9	······	0.959(0.623-1.478)	0.850
	Penalized weighted median		 	1.027(0.644-1.637)	0.912
	MR-PRESSO	9		1.011(0.658-1.554)	0.960
Triglycerides	IVW	21		1.078(0.782-1.484)	0.647
	MR-Egger	21	+	1.020(0.528-1.971)	0.953
	Weighted median	21		0.953(0.642-1.413)	0.810
	Simple mode	21		0.960(0.498-1.851)	0.905
	Weighted mode	21	II	0.972(0.578-1.636)	0.917
	BWMR	21		1.084(0.800-1.469)	0.601
	Penalized weighted median	21	I	0.952(0.649-1.396)	0.800
	MR-PRESSO	21		1.078(0.782-1.484)	0.652

FIGURE 3

Univariable MR results of circulating lipids traits and periodontitis of the validation cohort. The red dots represent the estimates using MR analysis, and the black bars represent the 95% confidence intervals of estimates. The OR>1 indicates increased risk while<1 indicates decreased risk. SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IVW, inverse variance weighted; BWMR, Bayesian weighted Mendelian randomization; HDL- cholesterol, high-density lipoprotein cholesterol; LDL- cholesterol, low-density lipoprotein cholesterol.

Korean National Health and Nutrition Examination Survey, showed that the TG/HDL-C ratio was a significant positive correlation with the prevalence of periodontitis after adjusting for variables such as sex, age, BMI, and dyslipidemia (OR=1.23, 95% CI=1.02–1.48, *P*-value<0.001) (41). Several cross-sectional studies also found that the mean values of salivary oxidative stress markers and periodontal clinical parameters (PD, CAL) had an extremely significant positive correlation with TG, LDL-C, and TC


serum levels and were significantly negatively correlated with serum HDL-C levels (42, 43).

It is worth noting that the conclusions of observational studies can only reflect correlation and cannot draw causal inferences. We believe that the reasons for the association between the two in previous trials may be as follows: On the one hand, considering the ethical issues in randomized clinical trials on patients with hyperlipidemia, most clinical research results are from cross-

TABLE 3 Heterogeneity and pleiotropy tests of circulating lipids traits causally linked to periodontitis in the validation cohort.

Exposure	MR-PRESSO <i>P</i> -value for Global Test	IVW				MR-Egger test		
		Cochran's Q	df	<sup>2</sup>	P-value	Egger-intercept	SE	P-value
apo A1	0.953	17.688	30	0.000	0.963	0.0077	0.007	0.304
apo B	0.621	8.542	10	0.000	0.576	0.0211	0.016	0.224
HDL-C	0.830	18.587	25	0.000	0.816	-0.0007	0.008	0.937
LDL-C	0.173	11.999	8	0.333	0.151	0.0308	0.019	0.156
TG	0.077	30.168	20	0.337	0.067	0.0026	0.014	0.853

apo A1, Apolipoprotein A1; apo B, Apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; IVW, inverse variance weighted.



#### FIGURE 4

Multivariable MR results of circulating lipids traits and periodontitis. The red dots represent the estimates using MR analysis, and the black bars represent the 95% confidence intervals of estimates. The OR>1 indicates increased risk while<1 indicates decreased risk. SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IVW, inverse variance weighted; HDL- cholesterol, high-density lipoprotein cholesterol; LDL- cholesterol, low-density lipoprotein cholesterol.

sectional studies, which makes the conclusions vulnerable to reverse causality. For example, in a case-control study of 65,078 Korean participants, after a median follow-up of 5.19 years, periodontitis was associated with lower HDL-C levels ( $\beta$ =-0.0066 mmol/L, SE=0.0026, *P*-value = 0.013) and higher TG levels ( $\beta$ =0.0307 mmol/L, SE=0.0049, *P*-value< 0.001) (44). This seems to be because, during periodontitis, inflammatory factors [C-reactive protein (CRP), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-1 $\beta$  (IL-1 $\beta$ ), and IL-6] released into serum can promote adipose tissue lipolysis and inhibit lipoprotein lipase activity, increase the synthesis of TG, and reduce the clearance of TG and LDL-C (45).

On the other hand, it is difficult for existing epidemiological studies to adequately adjust for confounding factors such as gut microbiome, personal dietary habits, and lifestyle. The gut microbiome affects lipid metabolism and the development and progression of periodontitis. After performing fecal microbiota transplantation to high-fat mice, Zhou D et al. observed that the number of beneficial bacteria Christensenellaceae and Lactobacillus in the intestine increased, the disordered intestinal flora was partially corrected, lipid metabolism was also improved, and the levels of TG and total cholesterol decreased (46). Meta-analysis results also showed that the intake of probiotic preparations could increase the level of HDL-C and effectively improve dyslipidemia (47). These all indicate that the balance of intestinal flora can regulate the lipid metabolism process. Similarly, several clinical studies have shown that adjuvant probiotic Lactobacillus reuteri therapy can significantly improve clinical periodontal symptoms after initial periodontal treatment (48). It has also been found in animal experiments that oral administration of probiotics before and after the formation of periodontitis in mice can significantly reduce the inflammatory factors in periodontitis and relieve alveolar bone resorption and periodontal ligament destruction (49, 50). The above studies suggest that the intestinal flora may affect the immune regulation of periodontal tissue and alveolar bone metabolism through the intestinal immune system. A newly published MR study on gut microbiota and periodontitis also confirmed this causal relationship (51). Thirdly, smoking, as the common risk factor for dyslipidemia and periodontitis, would also affect clinical trials as a confounding factor (52, 53).

At the same time, other circulating lipid traits release several proinflammatory cytokines that may be involved in the initiation and progression of periodontitis when dyslipidemia occurs. Continuously aggregated lipids will undergo glycation and oxidative modifications, inducing inflammatory response and oxidative stress (54). Of those, it was confirmed that palmitic acid (PA) can activate Toll-like receptor 4 (TLR4)/the myeloid differentiation factor 8 (MyD88)/the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB)/the nuclear factor-κB (NF-κB) pathway and then induce the production of proinflammatory cytokines including IL-1 $\beta$  and IL-6 (55). Cholesterol crystals phagocytized by macrophages can also activate the NOD-like receptor protein 3 (NLRP3) inflammasome by inducing the release of cathepsin B, leading to the production and secretion of IL-1 $\beta$  and IL-6 (56, 57). The systemic inflammatory burden will be due to these proinflammatory cytokines through blood circulation, which may participate in the immune regulation of the periodontal microenvironment (58). On the other hand, oxidized low-density lipoprotein (ox-LDL) is induced to increase and accumulate locally due to dyslipidemia (59). Suzuki et al. observed that ox-LDL could act on human gingival epithelial cells to activate the NF-KB pathway and ultimately induce the production of IL-8 (60, 61). Some crosssectional studies also found that as the severity of periodontitis increased, the levels of ox-LDL in patients' serum and gingival crevicular fluid both increased (11, 40). Therefore, we speculate that dyslipidemia can directly promote the occurrence and development of periodontal inflammation by increasing the accumulation of ox-LDL in the gingival crevicular fluid.

The strength of our study is that it is the first to utilize a multivariable MR design to investigate the causal effect of serum levels of five circulating lipid traits on periodontitis risk. This is an excellent solution to the vertical pleiotropy caused by the interaction between the shape of circulating blood lipids to obtain the independent causal effect of each parameter on periodontitis. More importantly, the sample size in the two-sample MR study is vast, and its hierarchy of evidence is higher than that of observational studies, second only to RCT studies (62). At the same time, this study also has certain limitations. First, exposure and outcome data were from European populations, and the results were not broadly generalizable to other ethnicities. Second, only five circulating lipid traits were reflected in this study. Other lipidrelated characteristics were not analyzed, such as very low-density lipoprotein cholesterol, chylomicrons, ox-LDL, and fatty acids. Third, the periodontitis cohort that was the result of this study did not use the latest diagnostic criteria of the European Federation of Periodontology/the American Academy of Periodontology (EFP/ AAP) for periodontitis. To further explore whether each circulating blood lipid trait has different causal effects on periodontitis with dissimilar severities, it is still necessary to use GWAS with more accurate periodontitis staging and grading in the future.

## **5** Conclusion

In conclusion, our findings suggest that none of the five circulating lipid traits (apo A1, apo B, HDL-C, LDL-C, and TG) is causally associated with periodontitis. Further studies using GWAS datasets, which include more comprehensive circulating lipid traits and more accurate definitions of periodontitis, are needed to validate the findings.

### Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

# References

1. Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. *Nat Rev Dis Primers* (2017) 3:17038. doi: 10.1038/nrdp.2017.38

2. Jiao J, Jing W, Si Y, Feng X, Tai B, Hu D, et al. The prevalence and severity of periodontal disease in Mainland China: Data from the Fourth National Oral Health Survey (2015-2016). *J Clin Periodontol* (2021) 48(2):168–79. doi: 10.1111/jcpe.13396

3. Trindade D, Carvalho R, Machado V, Chambrone L, Mendes JJ, Botelho J. Prevalence of periodontitis in dentate people between 2011 and 2020: A systematic review and meta-analysis of epidemiological studies. *J Clin Periodontol* (2023) 50 (5):604–626. doi: 10.1111/jcpe.13769

### Ethics statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

### Author contributions

GH performed the univariable and multivariable MR analysis and drafted and critically revised the manuscript. CS, YY, WW, and AW contributed to the results and discussion and critically revised the manuscript. MH and LL contributed to the design of the project and critically revised the manuscript. YW conceived the study, supervised the statistical analysis, and critically revised the manuscript. All authors gave their final approval and agree to be accountable for all aspects of the work.

### Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2023.1214232/ full#supplementary-material

4. Genco RJ, Sanz M. Clinical and public health implications of periodontal and systemic diseases: An overview. *Periodontol 2000* (2020) 83(1):7–13. doi: 10.1111/prd.12344

5. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. *Nat Rev Cardiol* (2021) 18(10):689-700. doi: 10.1038/s41569-021-00541-4

6. Hong N, Lin Y, Ye Z, Yang C, Huang Y, Duan Q, et al. The relationship between dyslipidemia and inflammation among adults in east coast China: A cross-sectional study. *Front Immunol* (2022) 13:937201. doi: 10.3389/fimmu.2022.937201

7. Bitencourt FV, Nascimento GG, Costa SA, Orrico SRP, Ribeiro CCC, Leite FRM. The role of dyslipidemia in periodontitis. *Nutrients* (2023) 15(2):300. doi: 10.3390/ nu15020300

8. Lee S, Im A, Burm E, Ha M. Association between periodontitis and blood lipid levels in a Korean population. *J Periodontol* (2018) 89(1):28–35. doi: 10.1902/jop.2017.170111

9. Sayar F, Akhondi N, Fallah S, Moalemnia AA, Cheraghi A. Association of serum triglyceride level and gemfibrozil consumption with periodontal status. *J Periodontol* (2017) 88(5):457–63. doi: 10.1902/jop.2016.160366

10. Kemer Doğan ES, Kırzıoğlu FY, Doğan B, Fentoğlu Ö, Kale B. The effect of menopause on the relationship between hyperlipidemia and periodontal disease via salivary 8-hydroxy-2'-deoxyguanosine and myeloperoxidase levels. *Acta Odontol Scand* (2018) 76(2):92–7. doi: 10.1080/00016357.2017.1386798

11. Ishizuka M, Kato R, Moriya Y, Noguchi E, Koide Y, Inoue S, et al. Changes in apolipoprotein B and oxidized low-density lipoprotein levels in gingival crevicular fluids as a result of periodontal tissue conditions. *J Periodontal Res* (2017) 52(3):594–602. doi: 10.1111/jre.12427

12. Darby I. Risk factors for periodontitis & peri-implantitis. Periodontol 2000 (2022) 90(1):9-12. doi: 10.1111/prd.12447

13. Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. *J Clin Lipidol* (2014) 8 (2):206–16. doi: 10.1016/j.jacl.2013.12.011

14. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* (2013) 37 (7):658–65. doi: 10.1002/gepi.21758

15. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet (1986) 1(8479):507–8. doi: 10.1016/S0140-6736(86)92972-7

16. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. *JAMA* (2021) 326 (16):1614–21. doi: 10.1001/jama.2021.18236

17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* (2002) 106(25):3143–421. doi: 10.1161/circ.106.25.3143

18. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* (2020) 41(1):111–88. doi: 10.1093/eurheartj/ehz455

19. Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. *Can J Cardiol* (2021) 37(8):1129–50. doi: 10.1016/j.cjca.2021.03.016

 Feingold KR. Introduction to lipids and lipoproteins. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al, editors. *Endotext*. South Dartmouth (MA): MDText.com, Inc (2000). Available at: https://www.ncbi.nlm.nih. gov/books/NBK305896/.

21. Lindahl M, Petrlova J, Dalla-Riva J, Wasserstrom S, Rippe C, Domingo-Espin J, et al. ApoA-I Milano stimulates lipolysis in adipose cells independently of cAMP/PKA activation. J Lipid Res (2015) 56(12):2248–59. doi: 10.1194/jlr.M054767

22. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. *Nat Genet* (2021) 53(2):185–94. doi: 10.1038/s41588-020-00757-z

23. Richardson TG, Leyden GM, Wang Q, Bell JA, Elsworth B, Davey Smith G, et al. Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. *PloS Biol* (2022) 20(2):e3001547. doi: 10.1371/journal.pbio.3001547

24. Collins R. What makes UK Biobank special? Lancet (2012) 379(9822):1173-4. doi: 10.1016/S0140-6736(12)60404-8

25. Shungin D, Haworth S, Divaris K, Agler CS, Kamatani Y, Keun Lee M, et al. Genome-wide analysis of dental caries and periodontitis combining clinical and self-reported data. *Nat Commun* (2019) 10(1):2773. doi: 10.1038/s41467-019-10630-1

26. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* (2014) 23(R1):R89–98. doi: 10.1093/hmg/ddu328

27. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. PhenoScanner: a database of human genotype-phenotype associations. *Bioinformatics* (2016) 32(20):3207-9. doi: 10.1093/bioinformatics/btw373

28. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Stat Med* (2016) 35(11):1880–906. doi: 10.1002/sim.6835

29. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol* (2013) 42(5):1497–501. doi: 10.1093/ije/dyt179

30. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res* (2020) 4:186. doi: 10.12688/wellcomeopenres.15555.2

31. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* (2015) 44(2):512–25. doi: 10.1093/ije/dyv080

32. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol* (2016) 40(4):304–14. doi: 10.1002/gepi.21965

33. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* (2017) 46(6):1985–98. doi: 10.1093/ije/dyx102

34. Zhao J, Ming J, Hu X, Chen G, Liu J, Yang C. Bayesian weighted Mendelian randomization for causal inference based on summary statistics. *Bioinformatics* (2020) 36(5):1501–8. doi: 10.1093/bioinformatics/btz749

35. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife* (2018) 7:e34408. doi: 10.7554/eLife.34408

36. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* (2018) 50(5):693–8. doi: 10.1038/s41588-018-0099-7

37. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol* (2015) 181 (4):251–60. doi: 10.1093/aje/kwu283

38. Grant AJ, Burgess S. Pleiotropy robust methods for multivariable Mendelian randomization. *Stat Med* (2021) 40(26):5813–30. doi: 10.1002/sim.9156

39. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. *Stat Med* (2021) 40(25):5434–52. doi: 10.1002/sim.9133

40. Fentoğlu Ö, Tözüm Bulut M, Doğan B, Kırzıoğlu FY, Kemer Doğan ES. Is the relationship between periodontitis and hyperlipidemia mediated by lipoproteinassociated inflammatory mediators? *J Periodontal Implant Sci* (2020) 50(3):135–45. doi: 10.5051/jpis.2020.50.3.135

41. Lee YC, Lee JW, Kwon YJ. Comparison of the triglyceride glucose (TyG) index, triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, and metabolic score for insulin resistance (METS-IR) associated with periodontitis in Korean adults. *Ther Adv Chronic Dis* (2022) 13:20406223221122671. doi: 10.1177/20406223221122671.

42. Sayar F, Fallah S, Akhondi N, Jamshidi S. Association of serum lipid indices and statin consumption with periodontal status. *Oral Dis* (2016) 22(8):775–80. doi: 10.1111/odi.12545

43. Lutfioğlu M, Aydoğdu A, Atabay VE, Sakallioğlu EE, Avci B. Gingival crevicular fluid oxidative stress level in patients with periodontal disease and hyperlipidemia. *Braz Oral Res* (2017) 31:e110. doi: 10.1590/1807-3107bor-2017.vol31.0110

44. Song TJ, Kim JW, Kim J. Oral health and changes in lipid profile: A nationwide cohort study. *J Clin Periodontol* (2020) 47(12):1437–45. doi: 10.1111/jcpe.13373

45. Fentoğlu Ö, Köroğlu BK, Hiçyılmaz H, Sert T, Özdem M, Sütçü R, et al. Proinflammatory cytokine levels in association between periodontal disease and hyperlipidaemia. *J Clin Periodontol* (2011) 38(1):8–16. doi: 10.1111/j.1600-051X.2010.01644.x

46. Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. *Sci Rep* (2017) 7(1):1529. doi: 10.1038/s41598-017-01751-y

47. Li C, Li X, Han H, Cui H, Peng M, Wang G, et al. Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: A meta-analysis of randomized, controlled trials. *Med (Baltimore)* (2016) 95(26):e4088. doi: 10.1097/MD. 000000000004088

48. Canut-Delgado N, Giovannoni ML, Chimenos-Küstner E. Are probiotics a possible treatment of periodontitis? Probiotics against periodontal disease: a systematic review. *Br Dent J* (2021). doi: 10.1038/s41415-021-3624-5

49. Jia L, Tu Y, Jia X, Du Q, Zheng X, Yuan Q, et al. Probiotics ameliorate alveolar bone loss by regulating gut microbiota. *Cell Prolif* (2021) 54(7):e13075. doi: 10.1111/ cpr.13075

50. Shimabukuro N, Cataruci ACS, Ishikawa KH, de Oliveira BE, Kawamoto D, Ando-Suguimoto ES, et al. Bifidobacterium strains present distinct effects on the control of alveolar bone loss in a periodontitis experimental model. *Front Pharmacol* (2021) 12:713595. doi: 10.3389/fphar.2021.713595

51. Luo S, Li W, Li Q, Zhang M, Wang X, Wu S, et al. Causal effects of gut microbiota on the risk of periodontitis: a two-sample Mendelian randomization study. *Front Cell Infect Microbiol* (2023) 13:1160993. doi: 10.3389/fcimb.2023.1160993

52. Reynolds MA. Modifiable risk factors in periodontitis: at the intersection of aging and disease. *Periodontol 2000* (2014) 64(1):7–19. doi: 10.1111/prd.12047

53. Li Z, Zhu G, Chen G, Luo M, Liu X, Chen Z, et al. Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018. *Lipids Health Dis* (2022) 21(1):111. doi: 10.1186/s12944-022-01721-y

54. Gordon S. Macrophage heterogeneity and tissue lipids. J Clin Invest (2007) 117 (1):89–93. doi: 10.1172/JCI30992

55. Korbecki J, Bajdak-Rusinek K. The effect of palmitic acid on inflammatory response in macrophages: an overview of molecular mechanisms. *Inflammation Res* (2019) 68(11):915–32. doi: 10.1007/s00011-019-01273-5

56. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. *Nature* (2012) 481(7381):278–86. doi: 10.1038/nature10759

57. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature* (2010) 464(7293):1357–61. doi: 10.1038/nature08938

58. Cekici A, Kantarci A, Hasturk H, Van Dyke TE. Inflammatory and immune pathways in the pathogenesis of periodontal disease. *Periodontol 2000* (2014) 64(1):57–80. doi: 10.1111/prd.12002

59. Yang L, Sun J, Li M, Long Y, Zhang D, Guo H, et al. Oxidized low-density lipoprotein links hypercholesterolemia and bladder cancer aggressiveness by

promoting cancer stemness. Cancer Res (2021) 81(22):5720-32. doi: 10.1158/0008-5472.CAN-21-0646

60. Suzuki K, Sakiyama Y, Usui M, Obama T, Kato R, Itabe H, et al. Oxidized lowdensity lipoprotein increases interleukin-8 production in human gingival epithelial cell line Ca9-22. J Periodontal Res (2010) 45(4):488–95. doi: 10.1111/j.1600-0765.2009.01263.x

61. Nagahama Y, Obama T, Usui M, Kanazawa Y, Iwamoto S, Suzuki K, et al. Oxidized low-density lipoprotein-induced periodontal inflammation is associated with the up-regulation of cyclooxygenase-2 and microsomal prostaglandin synthase 1 in human gingival epithelial cells. *Biochem Biophys Res Commun* (2011) 413(4):566–71. doi: 10.1016/j.bbrc.2011.09.002

62. Zhao SS, Mackie SL, Zheng J. Why clinicians should know about Mendelian randomization. *Rheumatol (Oxford)* (2021) 60(4):1577–9. doi: 10.1093/rheumatology/ keab007